VivoSim Labs Files 8-K on Shareholder Votes & Financials
Ticker: VIVS · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1497253
| Field | Detail |
|---|---|
| Company | Vivosim Labs, Inc. (VIVS) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financial-reporting, sec-filing
TL;DR
VivoSim Labs filed an 8-K on Dec 16, 2025, covering shareholder votes and financials.
AI Summary
VivoSim Labs, Inc. filed an 8-K on December 18, 2025, reporting on matters submitted to a vote of security holders and financial statements as of December 16, 2025. The company, formerly known as Organovo Holdings, Inc., is based in San Diego, California.
Why It Matters
This filing indicates important corporate actions and financial reporting by VivoSim Labs, Inc., providing transparency to investors regarding company governance and financial health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and financial information, not indicating any immediate operational or financial distress.
Key Numbers
- 001-35996 — SEC File Number (Identifies the company's filing history with the SEC.)
- 271488943 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- VivoSim Labs, INC. (company) — Registrant
- Organovo Holdings, Inc. (company) — Former company name
- December 16, 2025 (date) — Date of earliest event reported
- December 18, 2025 (date) — Filing date
- San Diego, California (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the significance of the 'Financial Statements and Exhibits' item?
This item signifies that the company is providing updated financial statements and related exhibits as part of this current report.
When did VivoSim Labs, Inc. change its name from Organovo Holdings, Inc.?
The filing mentions 'Organovo Holdings, Inc.' as a former company name but does not specify the date of the name change in the provided excerpt.
What is the primary business of VivoSim Labs, Inc.?
VivoSim Labs, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Where are VivoSim Labs, Inc.'s principal executive offices located?
The principal executive offices are located at 11555 Sorrento Valley Rd Suite 100, San Diego, California, 92121.
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2025-12-18 16:05:25
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value VIVS The Nasdaq Stock Mar
Filing Documents
- vivs-20251216.htm (8-K) — 79KB
- 0001193125-25-324794.txt ( ) — 184KB
- vivs-20251216.xsd (EX-101.SCH) — 24KB
- vivs-20251216_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 16, 2025, VivoSim Labs, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Of the 2,607,962 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issued and outstanding as of the October 17, 2025 record date, 972,769 shares, or 37.29%, constituting a quorum, were represented at the Annual Meeting either virtually or by proxy. A description of each proposal voted upon at the Annual Meeting is described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 3, 2025 (the "Proxy Statement").Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal. (1) Election of Directors . The Company's stockholders elected Douglas Jay Cohen and David Gobel as Class II directors, each to hold office until the 2028 Annual Meeting of Stockholders and until his respective successor is elected and qualified. The following table shows the tabulation of the votes cast "For" and "Withheld" for each of Mr. Cohen and Mr. Gobel as well as the "Broker Non-Votes" submitted for this proposal: Director For Withheld Broker Non-Votes Douglas Jay Cohen 212,079 15,531 745,159 Director For Withheld Broker Non-Votes David Gobel 212,420 15,190 745,159 (2) Ratification of Auditors . The Company's stockholders ratified the appointment of Rosenberg Rich Baker Berman P.A. as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, with the approval of 97.91% of the votes cast. The following table shows the tabulation of the votes cast "For" and "Against" this proposal as well as the "Abstentions" submitted for this proposal: For Against Abstentions 935,525 19,923 17,321 (3) Advisory Vote on the Compensation of Named Executive Officer
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VivoSim Labs, Inc. Date: December 18, 2025 By: /s/ Keith Murphy Name: Keith Murphy Title: Executive Chairman